7154 POSTER Hypothyroidism and Macrocytosis as Surrogate Markers for Response and Survival in Patients With Advanced Renal Cell Carcinoma Treated With Sunitinib as First-line Therapy

Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer

“…In one retrospective study by Wolter et al (128) conducted in 40 mRCC patients, a longer mPFS (10.3 vs. 3.6 months) and mOS (18.2 vs. 6.6 months) were reported in patients with thyroid dysfunction than in those with normal thyroid function. Subclinical hypothyroidism diagnosed during the first 2 months of treatment has also been reported to be associated with survival (128)(129)(130). Inconsistent results were reported in a prospective study of 111 mRCC patients treated with sunitinib, that did not find any relationship between abnormal thyroid function and PFS (18.9 vs. 15.9 months) (131).…”

“…Hand-foot syndrome of any grade is approximately reported in up to half of patients receiving TKIs, with 9% patients showing grade 3 or 4 hand and foot syndrome. This adverse event is related to dermal endothelial cell apoptosis due to inhibition of VEGFR and PDGFR (platelet-derived growth factor receptor) in (133)(134)(135) TKIs may also mediate skin toxicity when secreted in the eccrine glands of the skin, which are rich in c-KIT (128)(129)(130). Pone retrospective study reported hand-foot syndrome to be associated with improved OS, PFS, and ORR.…”